Ann Arbor, Mich.-based startup Histosonics Inc. has raised a $54 million series C round to get its Robotically Assisted Sonic Therapy (RAST) platform through regulators in U.S. and Europe, conduct further clinical testing and launch the platform. The platform is based on histotripsy, which uses sound energy to generate pressure to liquify and destroy targeted cells as a subcellular level. The technology is expected to improve treatment precision, eliminate radiation exposure and provide faster healing to patients. Read More
